Cleaved-PARP1 (A214) Antibody

What is Cleaved-PARP1 (D214) Antibody and what specific epitope does it recognize?

Cleaved-PARP1 (D214) antibody is a research reagent specifically designed to detect the 89 kDa fragment of PARP1 (Poly(ADP-ribose) polymerase 1) that results from cleavage by caspase-3 and caspase-7 during apoptosis. The antibody recognizes a neoepitope created at the cleavage site between Asp214 and Gly215 in human PARP1. This cleavage event separates the PARP1 amino-terminal DNA-binding domain (24 kDa) from the carboxy-terminal catalytic domain (89 kDa) . The specificity for this cleavage site makes these antibodies valuable markers for detecting cells undergoing apoptosis in various experimental systems.

Unlike antibodies that recognize the full-length protein, Cleaved-PARP1 (D214) antibodies only bind to the cleaved fragment, enabling researchers to specifically assess apoptotic activity. Most commercially available antibodies in this category are raised against synthetic peptides derived from the region surrounding D214 of human PARP1 .

What are the recommended applications and dilutions for Cleaved-PARP1 (D214) antibody?

Cleaved-PARP1 (D214) antibodies can be used in multiple experimental applications with specific recommended dilutions:

These dilutions should be optimized for specific experimental conditions and sample types. For Western blot applications, the antibody typically detects a band at 89 kDa representing the large cleaved fragment of PARP1 .

How should I prepare samples to maximize detection of Cleaved-PARP1?

For optimal detection of Cleaved-PARP1 (D214), sample preparation should include the following methodological considerations:

• Apoptosis induction: Staurosporine treatment is widely used as a positive control for cleaved PARP1 detection. Based on the search results, exposure to staurosporine for 1-6 hours effectively induces caspase-3 activation and subsequent PARP1 cleavage .

• Cell lysis buffer: Use a buffer that preserves protein integrity while ensuring complete extraction. Standard RIPA buffer supplemented with protease inhibitors is often suitable. For subcellular fractionation studies, specific nuclear and cytoplasmic extraction buffers are recommended to track the translocation of the 89-kDa PARP1 fragment .

• Protein loading control: When performing Western blot, ensure consistent protein loading (typically 20-30 μg per lane) and include appropriate loading controls .

• Positive controls: Include apoptosis-induced samples (e.g., staurosporine-treated A549, HeLa, or HSC-T6 cells) as positive controls to validate antibody performance .

For immunofluorescence studies, fixation with 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100 typically yields good results for detecting cleaved PARP1 localization during apoptosis .

How does the 89-kDa PARP1 cleavage fragment function in apoptotic signaling pathways?

The 89-kDa PARP1 cleavage fragment plays significant roles beyond being a marker of apoptosis. Recent research reveals it serves as a cytoplasmic poly(ADP-ribose) (PAR) carrier with specific signaling functions:

• PAR transport to cytoplasm: Following caspase cleavage, the 89-kDa PARP1 fragment, which retains the automodification domain and catalytic domain, is translocated from the nucleus to the cytoplasm while carrying PAR polymers. This translocation mechanism is dependent on caspase-mediated cleavage at D214, as PARP1 D214G mutants (lacking the caspase cleavage site) fail to translocate to the cytoplasm even under apoptotic conditions .

• AIF interaction: In the cytoplasm, the poly(ADP-ribosyl)ated 89-kDa PARP1 fragment interacts with Apoptosis-Inducing Factor (AIF) via PAR polymers. This interaction is critical for subsequent AIF translocation from mitochondria to the nucleus, which leads to chromatin condensation and DNA fragmentation. The interaction requires both proper fragmentation by caspase and intact PAR polymers on the 89-kDa fragment .

• Regulation of interferon responses: The truncated PARP1 (tPARP1) facilitates the generation of interferon-β (IFN-β) in apoptotic cells. Experiments comparing cleavable wild-type PARP1 and non-cleavable D214N mutant forms showed that only cells expressing wild-type PARP1 (which can be cleaved) produce significant IFN-β when exposed to apoptotic stimuli .

These findings suggest that the 89-kDa PARP1 fragment actively participates in apoptotic and inflammatory signaling, rather than being a mere by-product of PARP1 inactivation.

What are the critical considerations for detecting Cleaved-PARP1 in different subcellular compartments?

Tracking the subcellular localization of Cleaved-PARP1 requires specific experimental approaches to capture its dynamic behavior during apoptosis:

• Subcellular fractionation: To accurately detect the translocation of the 89-kDa PARP1 fragment, proper nuclear/cytoplasmic fractionation is essential. Research indicates that after staurosporine treatment, 89-kDa PARP1 fragments appear in cytoplasmic fractions within 4 hours of exposure. This fractionation should be validated with appropriate markers for nuclear (e.g., Lamin B) and cytoplasmic (e.g., GAPDH) compartments .

• Immunofluorescence optimization: For in situ detection, standard IF protocols may need optimization, including:

  • Extended primary antibody incubation (overnight at 4°C)

  • Signal amplification methods for detecting low abundant cytoplasmic signals

  • Confocal microscopy with z-stack analysis to distinguish nuclear versus cytoplasmic signals

• Dual staining approaches: Combining Cleaved-PARP1 antibody with markers for specific organelles (mitochondria, endoplasmic reticulum) can reveal interactions with other cellular compartments during apoptotic progression. Co-staining with AIF is particularly informative to visualize the interaction between the 89-kDa PARP1 fragment and AIF in cytoplasmic and mitochondrial compartments .

• Live-cell imaging: For dynamic studies, GFP-tagged PARP1 constructs can be used to track localization in real-time, though care must be taken as tags may alter trafficking. FRAP (Fluorescence Recovery After Photobleaching) experiments reveal that staurosporine exposure affects the mobility of PARP1 at DNA damage sites, which can be blocked by caspase inhibitors (zVAD-fmk) .

How can Cleaved-PARP1 (D214) antibody be used to distinguish between apoptosis and other forms of cell death?

Distinguishing between different modes of cell death requires careful experimental design and interpretation when using Cleaved-PARP1 (D214) antibody:

• Apoptosis versus necrosis: Cleaved-PARP1 is specifically generated during caspase-dependent apoptosis. To distinguish from necrosis:

  • Include caspase inhibitor controls (e.g., zVAD-fmk) which should prevent PARP1 cleavage in apoptotic cells but not affect necrotic outcomes

  • Perform parallel assays for necrosis markers (e.g., cell membrane permeability, LDH release)

  • Analyze the pattern of PARP1 processing—apoptosis yields specific 89 kDa fragments, while in necrosis, different patterns of degradation may be observed

• Parthanatos versus apoptosis: In parthanatos (PARP1-dependent cell death without caspase activation), excessive PAR accumulation occurs without PARP1 cleavage. Differential diagnosis includes:

  • Western blot for full-length PARP1 and PAR polymers alongside cleaved PARP1

  • Testing with PARP inhibitors (e.g., PJ34, olaparib) which would block parthanatos but not affect caspase-mediated PARP1 cleavage

  • Analysis of nuclear AIF translocation patterns, which differ between mechanisms

• Flow cytometry multi-parameter approach: For quantitative distinction between death modes:

  • Combine Cleaved-PARP1 staining with Annexin V (early apoptosis) and propidium iodide (membrane integrity)

  • Include caspase activity probes (e.g., FLICA) to confirm caspase dependence

  • Analyze the timeline of marker appearance—typically Annexin V positivity precedes cleaved PARP1 detection in apoptosis

This multi-parameter approach enables more accurate classification of cell death mechanisms in complex biological systems.

What role does PARP1 cleavage play in modulating ADP-ribosylation during apoptosis?

PARP1 cleavage during apoptosis has complex effects on ADP-ribosylation processes:

• Maintenance of ADP-ribosylation activity: Interestingly, despite being cleaved, the 89-kDa PARP1 fragment retains catalytic activity. Research shows that this fragment can still carry poly(ADP-ribose) (PAR) polymers and potentially catalyze further ADP-ribosylation reactions. Experiments with PARP1 E988K mutant (which lacks catalytic activity) demonstrate that enzymatic activity of the cleaved fragment is functionally important for subsequent signaling events .

• Altered substrate specificity: PARP1 cleavage separates the DNA-binding domain from the catalytic domain, potentially altering substrate recognition. Evidence suggests that truncated PARP1 (tPARP1) can mediate ADP-ribosylation of RNA polymerase III, which affects downstream interferon responses during apoptosis. This indicates a shift in PARP1 function from DNA repair to immune signaling after cleavage .

• Compartmentalization of ADP-ribosylation: Cleaved PARP1 translocation to the cytoplasm enables ADP-ribosylation of cytoplasmic proteins that would normally not encounter active PARP1. This creates a novel signaling mechanism where nuclear PAR synthesis is coupled with cytoplasmic PAR-dependent signaling through the cleaved fragment's translocation .

• Regulation by inhibitors: While caspase inhibitors (e.g., zVAD-fmk) prevent PARP1 cleavage, PARP inhibitors (e.g., PJ34, olaparib) block the enzymatic activity without affecting the cleavage event. This distinction has important implications for understanding the dual roles of PARP1 structure versus activity in apoptotic signaling .

Experimentally, researchers can distinguish these roles by using PARP1 mutants that either lack catalytic activity (E988K) or are resistant to caspase cleavage (D214G/D214N), providing insight into the separable functions of PARP1 fragmentation versus its enzymatic activity.

How can I optimize Cleaved-PARP1 (D214) antibody performance for flow cytometry applications?

Flow cytometric detection of Cleaved-PARP1 requires specific optimization strategies:

• Fixation and permeabilization protocol:

  • Use freshly prepared 4% paraformaldehyde for fixation (10-15 minutes at room temperature)

  • For permeabilization, methanol (-20°C, 10 minutes) works well for nuclear protein access

  • Alternative permeabilization with saponin (0.1%) may be gentler but requires optimization

  • Critical step: thorough washing between fixation and permeabilization prevents artifactual aggregation

• Antibody titration and incubation conditions:

  • Starting dilution: 0.4 μg per 10^6 cells in 100 μl suspension

  • Optimum signal-to-noise ratio typically requires experimental titration for each cell type

  • Extended incubation (2-4 hours at room temperature or overnight at 4°C) improves signal intensity

  • Include parallel samples with isotype control to establish background levels

• Positive controls and validation:

  • Always include untreated cells as negative control

  • Staurosporine-treated cells (1 μM for 3 hours) provide reliable positive control

  • Block with caspase inhibitor (zVAD-fmk) in parallel samples to confirm specificity

• Multi-parameter analysis strategy:

  • Combine with cell cycle dyes (e.g., DAPI, propidium iodide) to correlate apoptosis with cell cycle phase

  • Include Annexin V in separate panel to distinguish early versus late apoptotic cells

  • Consider including mitochondrial membrane potential dyes to correlate with intrinsic apoptosis pathway

  • Gate analysis should account for debris and cell shrinkage characteristic of apoptosis

Example data from flow cytometric analysis shows clear differentiation between untreated cells (red) and staurosporine-treated cells (green) when stained with Cleaved-PARP1 (D214) antibody, with unstained cells serving as negative control (blue) .

Why might I observe inconsistent band sizes when using Cleaved-PARP1 (D214) antibody in Western blot?

Several factors can contribute to unexpected band patterns when detecting Cleaved-PARP1:

• Multiple PARP1 cleavage sites: While caspase-3/7 primarily cleave PARP1 at D214, secondary cleavage events by other proteases may generate additional fragments during extensive apoptosis. This can result in bands of varying molecular weights .

• Post-translational modifications: The 89-kDa PARP1 fragment can carry poly(ADP-ribose) polymers of varying lengths, leading to smearing or higher molecular weight bands than expected. As noted in the Elabscience antibody datasheet, "The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane" .

• Cross-reactivity with other PARP family members: Some antibodies may cross-react with other PARP family proteins (e.g., PARP2, PARP3) that undergo similar cleavage during apoptosis. Verify antibody specificity using PARP1 knockout or knockdown samples .

• Sample preparation issues: Incomplete denaturation, protein degradation during sample preparation, or insufficient protease inhibition can all affect band pattern. Ensure samples are freshly prepared and properly denatured in sample buffer containing SDS and reducing agents .

To address these issues, researchers should:

• Include appropriate positive controls (e.g., staurosporine-treated cells)

• Perform parallel detection with antibodies against both full-length and cleaved PARP1

• Consider using caspase inhibitors (zVAD-fmk) to confirm the specificity of detected bands

• Optimize gel percentage (8-12% is typically suitable) for optimal resolution of the 89 kDa fragment

What experimental factors affect the temporal detection of Cleaved-PARP1 during apoptosis?

The timing of Cleaved-PARP1 detection is influenced by multiple experimental variables:

• Cell type-specific kinetics: Different cell lines exhibit varying rates of apoptosis progression. As observed in research data, staurosporine induces visible PARP1 cleavage after just 1 hour in some cell lines, while others may require 4-6 hours for significant detection .

• Apoptotic stimulus intensity: The concentration and type of apoptotic stimulus significantly affect cleavage kinetics:

  • Staurosporine (1 μM): Typically induces detectable PARP1 cleavage within 1-3 hours

  • DNA damaging agents: Often show delayed kinetics (6-24 hours)

  • Death receptor ligands (e.g., FasL, TRAIL): May show intermediate kinetics (3-8 hours)

• Culture conditions: Confluence level, serum starvation, and metabolic state of cells affect their sensitivity to apoptotic stimuli and subsequent PARP1 cleavage rates. Standardize culture conditions to ensure reproducible timing .

• Detection method sensitivity: The temporal detection window varies with methodology:

  • Western blot: Often requires substantial population-level cleavage (>10-20% of cells)

  • Flow cytometry: Can detect earlier events in subpopulations

  • Immunofluorescence: Allows observation of early events in individual cells

To standardize temporal detection:

• Include multiple time points in initial experiments (e.g., 1, 3, 6, 12, 24 hours)

• Correlate PARP1 cleavage with other apoptotic markers (caspase-3 activation, Annexin V exposure)

• Consider using synchronization methods if cell cycle phase affects apoptosis susceptibility

• Monitor both nuclear retention and cytoplasmic translocation of cleaved fragments

How can Cleaved-PARP1 (D214) antibody be utilized in DNA damage and repair research?

Cleaved-PARP1 (D214) antibody offers unique insights into DNA damage response mechanisms:

• Discriminating repair versus apoptosis decisions: Full-length PARP1 is essential for DNA repair, while its cleavage signals commitment to apoptosis. Cleaved-PARP1 (D214) antibody enables researchers to determine when cells transition from attempting repair to initiating apoptosis after DNA damage. This transition point can be quantified by comparing the ratio of full-length to cleaved PARP1 over time .

• Microirradiation studies: The search results describe innovative microirradiation techniques combined with fluorescently-tagged PARP1 to study recruitment dynamics at DNA damage sites. Researchers observed that "Short-term exposure (2 h) to staurosporine suppressed PARP1-GFP recruitment and accelerated dissociation at DNA lesions, whereas zVAD-fmk blocked the effect" . Similar approaches using Cleaved-PARP1 antibodies can reveal how caspase activation affects PARP1 function at damage sites.

• ADP-ribosylation patterns: Cleaved-PARP1 retains catalytic activity but exhibits altered targeting. Researchers can use Cleaved-PARP1 (D214) antibody alongside anti-PAR antibodies to distinguish between ADP-ribosylation patterns generated by full-length versus cleaved PARP1. This approach revealed that "serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage" .

• PARP inhibitor response monitoring: In PARP inhibitor studies (e.g., cancer therapeutics), Cleaved-PARP1 (D214) antibody helps distinguish between inhibition of enzymatic activity versus induction of apoptosis. This distinction is critical when evaluating why certain cancers respond differently to PARP inhibitors .

Methodologically, combining Cleaved-PARP1 detection with DNA damage markers (γH2AX, 53BP1) in multiplexed immunofluorescence provides temporal and spatial resolution of repair versus apoptosis decisions at the single-cell level.

What are the considerations for using site-specific PARP1 mutants in combination with Cleaved-PARP1 (D214) antibody?

Site-specific PARP1 mutants are powerful tools for mechanistic studies when used alongside Cleaved-PARP1 antibodies:

• Cleavage-resistant mutants: PARP1 D214G and D214N mutants prevent caspase-mediated cleavage. The search results describe experiments where "PARP1 D214G-GFP did not produce PAR after 4-h exposure to staurosporine" and "In PARP1 shRNA-expressing HeLa cells, staurosporine exposure did not result in the translocation of PARP1 D214G-GFP and PAR to the cytoplasm" . These mutants help dissect the specific consequences of PARP1 cleavage.

Key considerations when using these mutants:

• Confirm expression levels match endogenous PARP1 to avoid overexpression artifacts

• Verify the cleavage resistance phenotype by Western blot

• Consider complementation in PARP1-knockout backgrounds for clean interpretation

• Note that D214G/N mutations do not affect catalytic activity, only cleavability

• Catalytically inactive mutants: PARP1 E988K mutant lacks ADP-ribosylation activity but retains normal structure. Research shows that "PARP1 E988K-GFP was cleaved after a 2-h exposure to staurosporine" but could not produce PAR . This mutant helps separate cleavage events from catalytic consequences.

When using this mutant:

• Confirm the mutation completely abolishes catalytic activity (PAR formation)

• Verify normal recruitment to DNA damage sites despite catalytic inactivity

• In combined studies, distinguish E988K effects from D214G/N effects to separate structure from function

• Antibody epitope considerations: When using mutants near the D214 region, researchers should verify that the mutations do not affect antibody binding. Some Cleaved-PARP1 antibodies recognize neo-epitopes that might be altered by nearby mutations. Control experiments should include:

• Validating antibody reactivity against the specific mutant after induced cleavage

• Using alternative detection methods (e.g., tag detection) if epitope recognition is compromised

• Considering alternative cleavage-site antibodies if available

The combination of site-specific mutants with Cleaved-PARP1 antibodies has revealed critical insights, such as the finding that "only the D214N mutant but not the wild-type caspase-cleavable PARP1 suppressed the generation of IFN-β in poly(dA-dT)-mediated apoptotic cells" .

How is Cleaved-PARP1 detection being integrated with advances in single-cell analysis technologies?

Cleaved-PARP1 detection is evolving with single-cell technologies to provide unprecedented insights into apoptosis heterogeneity:

• Single-cell proteomics: Mass cytometry (CyTOF) can now incorporate Cleaved-PARP1 antibodies into panels with 30+ other markers. This enables comprehensive characterization of apoptotic cell states in heterogeneous populations, correlating PARP1 cleavage with cell type markers, signaling pathway activation, and other apoptotic events at single-cell resolution .

• Spatial transcriptomics integration: Combining Cleaved-PARP1 immunofluorescence with in situ transcriptomics allows researchers to correlate apoptotic events with gene expression changes in tissue contexts. This approach can reveal how apoptotic cells influence neighboring cell transcriptional programs through paracrine signaling .

• Live-cell reporters: While traditional Cleaved-PARP1 antibodies require fixed cells, new FRET-based reporters that detect caspase-mediated PARP1 cleavage in real-time are being developed. These tools complement antibody-based detection for longitudinal single-cell studies of apoptosis dynamics .

• Microfluidic applications: Droplet-based single-cell analysis platforms can be adapted to detect Cleaved-PARP1 in circulation tumor cells or other rare populations, potentially offering new diagnostic approaches for monitoring therapy-induced apoptosis in patient samples .

Implementation considerations include:

• Optimization of fixation and permeabilization protocols for each platform

• Careful selection of fluorophores or metal tags to minimize spectral overlap

• Development of computational approaches to interpret complex single-cell apoptosis data

• Validation of single-cell findings with traditional bulk methods

What is the role of Cleaved-PARP1 in interferon responses and implications for immunological research?

Recent research has uncovered unexpected connections between PARP1 cleavage and immune signaling:

• Interferon-β production modulation: The search results reveal that "the enzymatic activity of tPARP1 facilitates the generation of IFN-β in apoptotic cells." Specifically, when cells were treated with poly(dA-dT) to induce apoptosis, IFN-β production was dependent on PARP1 cleavage, as non-cleavable PARP1 D214N mutants suppressed IFN-β generation .

• RNA polymerase III regulation: Truncated PARP1 (tPARP1) appears to mediate ADP-ribosylation of RNA polymerase III during apoptosis. This modification affects Pol III activity, which is critical for generating immunostimulatory RNA species. When cells were treated with Pol III inhibitor ML-60218, IFN-β production was dramatically reduced, confirming this mechanistic connection .

• DAMPs and immunogenic cell death: Cleaved-PARP1 and its associated PAR polymers may function as Damage-Associated Molecular Patterns (DAMPs) when released from dying cells. Detecting Cleaved-PARP1 in extracellular compartments could provide insights into how apoptotic cells trigger inflammatory responses in certain contexts .

Research applications include:

• Monitoring Cleaved-PARP1 in models of viral infection to understand virus-induced apoptosis and interferon responses

• Investigating how cancer therapies that induce PARP1 cleavage might influence anti-tumor immune responses

• Exploring how PARP inhibitors affect not only DNA repair but also immunomodulatory functions in therapeutic settings

Methodologically, researchers should consider:

• Combining Cleaved-PARP1 detection with interferon signaling readouts (pSTAT1, ISG expression)

• Including appropriate controls (PARP inhibitors, caspase inhibitors, PARP1 mutants)

• Validating findings across multiple cell types as the immunomodulatory effects may be context-dependent

This emerging area highlights how Cleaved-PARP1, beyond its role as an apoptosis marker, functions in broader cellular communication processes with significant implications for immunotherapy and inflammatory disease research.